Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments

The pharmacological treatment of cognitive impairments associated with schizophrenia is still a major unmet clinical need. Indeed, treatments with available antipsychotics generate highly variable cognitive responses among patients with schizophrenia. This has led to the general assumption that anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Torrisi, Sebastiano Alfio, Laudani, Samuele, Contarini, Gabriella, De Luca, Angelina, Geraci, Federica, Managò, Francesca, Papaleo, Francesco, Salomone, Salvatore, Drago, Filippo, Leggio, Gian Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694365/
https://www.ncbi.nlm.nih.gov/pubmed/33167370
http://dx.doi.org/10.3390/ph13110365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694365/
https://www.ncbi.nlm.nih.gov/pubmed/33167370
http://dx.doi.org/10.3390/ph13110365

Ejemplares similares